These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 18343806

  • 1. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [Abstract] [Full Text] [Related]

  • 2. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF, MONARK Study Group.
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [Abstract] [Full Text] [Related]

  • 3. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T, van der Lugt J, Bunupuradah T, Ananworanich J, Gorowara M, Phasomsap C, Jupimai T, Boonrak P, Pancharoen C, Burger D, Ruxrungtham K.
    J Antimicrob Chemother; 2009 Nov 30; 64(5):1080-6. PubMed ID: 19729375
    [Abstract] [Full Text] [Related]

  • 5. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR, Estrela RC, Suarez-Kurtz G, Schechter M, Cerbino-Neto J, Barroso PF.
    Ther Drug Monit; 2006 Apr 30; 28(2):175-9. PubMed ID: 16628127
    [Abstract] [Full Text] [Related]

  • 6. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW, Becker S, King MS, da Silva B, Klein C, Tokimoto D, Foit C, Calhoun D, Bernstein B, Hanna GJ.
    J Antimicrob Chemother; 2007 May 30; 59(5):957-63. PubMed ID: 17350990
    [Abstract] [Full Text] [Related]

  • 7. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B, Marcellin F, Cohen-Codar I, Flandre P, Boue F, Dellamonica P, Raffi F, Norton M, Van Philippe N, Delfraissy JF.
    Antivir Ther; 2008 May 30; 13(4):591-9. PubMed ID: 18672538
    [Abstract] [Full Text] [Related]

  • 8. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 30; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
    van der Lee M, Verweel G, de Groot R, Burger D.
    Antivir Ther; 2006 Aug 30; 11(4):439-45. PubMed ID: 16856617
    [Abstract] [Full Text] [Related]

  • 10. Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.
    Avettand-Fenoel V, Flandre P, Chaix ML, Ghosn J, Delaugerre C, Raffi F, Ngovan P, Cohen-Codar I, Delfraissy JF, Rouzioux C, MONARK Study Group.
    J Antimicrob Chemother; 2010 May 30; 65(5):1005-7. PubMed ID: 20299496
    [Abstract] [Full Text] [Related]

  • 11. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M, OK04 Study Group.
    AIDS; 2008 Jan 11; 22(2):F1-9. PubMed ID: 18097218
    [Abstract] [Full Text] [Related]

  • 12. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
    Eron JJ, Smeaton LM, Fiscus SA, Gulick RM, Currier JS, Lennox JL, D'Aquila RT, Rogers MD, Tung R, Murphy RL.
    J Infect Dis; 2000 May 11; 181(5):1622-8. PubMed ID: 10783117
    [Abstract] [Full Text] [Related]

  • 13. HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
    Bunupuradah T, Bowonwattanuwong C, Jirajariyavej S, Munsakul W, Klinbuayaem V, Sophonphan J, Mahanontharit A, Hirschel B, Ruxrungtham K, Ananworanich J, HIV STAR Study team.
    Antivir Ther; 2014 May 11; 19(6):579-86. PubMed ID: 24464590
    [Abstract] [Full Text] [Related]

  • 14. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
    Isaac A, Taylor S, Cane P, Smit E, Gibbons SE, White DJ, Drake SM, Khoo S, Back DJ.
    J Antimicrob Chemother; 2004 Aug 11; 54(2):498-502. PubMed ID: 15254024
    [Abstract] [Full Text] [Related]

  • 15. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.
    Pereira AS, Kashuba AD, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ, Cohen MS.
    J Infect Dis; 1999 Dec 11; 180(6):2039-43. PubMed ID: 10558966
    [Abstract] [Full Text] [Related]

  • 16. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Lazzarin A, Castagna A.
    J Med Virol; 2006 Dec 11; 78(12):1537-41. PubMed ID: 17063520
    [Abstract] [Full Text] [Related]

  • 17. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.
    J Antimicrob Chemother; 2007 Aug 11; 60(2):436-9. PubMed ID: 17556354
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
    van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D.
    Antivir Ther; 2007 Aug 11; 12(7):1127-32. PubMed ID: 18018771
    [Abstract] [Full Text] [Related]

  • 19. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C, Burri M, Shen Y, Rode R, Nadal D, Pediatric Infectious Disease Group of Switzerland, Swiss Mother and Child HIV Cohort Study (MoCHiV).
    Pediatr Infect Dis J; 2008 May 11; 27(5):431-7. PubMed ID: 18382386
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.
    J Antimicrob Chemother; 2008 Jan 11; 61(1):200-5. PubMed ID: 17999977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.